Compare · AMRX vs JAZZ
AMRX vs JAZZ
Side-by-side comparison of Amneal Pharmaceuticals Inc. (AMRX) and Jazz Pharmaceuticals plc (JAZZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMRX and JAZZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JAZZ is the larger of the two at $15.45B, about 2.1x AMRX ($7.36B).
- AMRX has been more active in the news (15 items in the past 4 weeks vs 14 for JAZZ).
- JAZZ has more recent analyst coverage (25 ratings vs 7 for AMRX).
- Company
- Amneal Pharmaceuticals Inc.
- Jazz Pharmaceuticals plc
- Price
- -
- -
- Market cap
- $7.36B
- $15.45B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 15
- 14
- Recent ratings
- 7
- 25
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Latest AMRX
- FDA Approval for DEXMETHYLPHENIDATE HYDROCHLORIDE issued to IMPAX LABS INC
- Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
- FDA Approval for KETAMINE HYDROCHLORIDE issued to AMNEAL
- Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers
- FDA Approval for FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE issued to IMPAX PHARMS
- FDA Approval for ISOTRETINOIN issued to AMNEAL PHARMS NY
- FDA Approval for ISOTRETINOIN issued to AMNEAL PHARMS NY
- SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.
- FDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMS
- FDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMS
Latest JAZZ
- Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
- Director Cozadd Bruce C exercised 86,500 units of Ordinary Shares at a strike of $136.18 and sold $16,235,517 worth of Ordinary Shares (68,808 units at $235.95), increasing direct ownership by 5% to 357,567 units (SEC Form 4) to cover withholding tax
- SVP, Chief Accounting Officer Carr Patricia exercised 1,250 units of Ordinary Shares at a strike of $140.03 and sold $326,910 worth of Ordinary Shares (1,413 units at $231.36), decreasing direct ownership by 2% to 6,512 units (SEC Form 4)
- SEC Form 144 filed by Jazz Pharmaceuticals plc
- SEC Form 4 filed by Jazz Pharmaceuticals plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Jazz Pharmaceuticals plc
- Director Cozadd Bruce C sold $1,295,040 worth of Ordinary Shares (6,000 units at $215.84) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 339,875 units (SEC Form 4)
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form 144 filed by Jazz Pharmaceuticals plc
- SEC Form 10-Q filed by Jazz Pharmaceuticals plc